Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06064656 · ClinicalTrials.gov registry record
A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)
A clinical trial, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- 131
- Enrollment target
NCT06064656 is a clinical trial that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 131 participants.
The verdict
NCT06064656 has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- 131 participants
- Enrollment target
Study Summary
Primary Objective(s): * To describe the demographic characteristics of people living with FOP and a matched cohort of non-FOP people living in the United States (U.S.) * To describe the prevalence of clinical characteristics of interest and the use of key medications in people living with FOP and a matched cohort of non-FOP people living in the U.S. * To compare the prevalence of key clinical characteristics and medication use in people living with FOP to a matched cohort of non-FOP people living in the U.S. * To estimate the crude mortality rate among people living with FOP
Interventions
- OTHER Non-Interventional
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2023-09-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06064656
The ClinicalTrials.gov registry entry for NCT06064656 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-Interventional is the first listed.
NCT06064656 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06064656 about?
NCT06064656 is a clinical study titled "A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)". Primary Objective(s): * To describe the demographic characteristics of people living with FOP and a matched cohort of non-FOP people living in the United States (U.S.) * To describe the prevalence of clinical characteristics of interest and the use of key medications in people living with FOP and a...
What is the current status of trial NCT06064656?
This trial is currently completed. The enrollment target is 131 participants. The study started on 2023-06-29. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT06064656?
The interventions under investigation include: Non-Interventional (OTHER).
Who is sponsoring clinical trial NCT06064656?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.